【摘要】 为了阐明乙型肝炎病毒YMDD变异对肝纤维化的影响。 4组共 170例患者治疗 (或观察 )前后分别用实时荧光PCR法检测其外周血中的HBVDNA及YMDD变异株 ,用RIA法检测肝纤维化血清指标。治疗后未变异组与变异组比较肝纤维化血清指标差异不显著 (P >0 0 5 ) ,其它组之间比较差异有显著意义 (P <0 0 5 ) ,各组治疗前后比较血清HBVDNA及肝纤维化血清指标差异有显著意义 (P <0 0 5 )。结果显示拉米夫定能有效地抑制HBV复制 ,延缓或逆转肝纤维化进程 ,但是 ,YMDD变异使其对HBV复制的抑制作用减弱 ,延缓或逆转肝纤维化进程的作用也受影响更多还原

【Abstract】 To expound the influence of the variation of YMDD in hepatitis B virus on the hepatic fibrosis. 4 groups (170 sera samples) were detected HBV DNA and YMDD mutation in serum by real-time fluorimetry PCR between pretreatment and post-treatment. They were detected hepatic fibrosis serum markers by RIA. There was no significant difference in the hepatic fibrosis serum markers between the group of non variation and variation at post-treatment (P>0.05). There was a significant difference among the other groups (P<0.05). Each group had a significant difference in the HBV DNA contents in sera and hepatic fibrosis serum markers between at the beginning and end of treatment (P<0.05). The result showed that Lamivudine could efficaciously control HBV’s reproduction, postpone or reverse hepatic fibrosis developing. But the Variation of YMDD would affect its curative effect.更多还原